• clinical
  • This disorder is differentiated from all other forms of HL, which are commonly referred to as classical Hodgkin lymphomas (cHLs), by characteristic pathologic and clinical features. (uptodate.com)
  • cohorts
  • Subjects enrolled in the preliminary efficacy cohorts must have relapsed, refractory, or persistent follicular lymphoma (persistent disease defined as computed tomography (CT) positive for 3 months after last treatment), and must not have received anti-CD20 targeted therapy within 3 months of receiving the first dose of test article. (clinicaltrials.gov)
  • cells
  • Burkitt lymphoma grows from B-cells, one type of lymphocyte. (cityofhope.org)
  • This type of lymphoma starts with B cells. (cityofhope.org)
  • In 1 patient with SD, however, persistence of CD20-positive cells within lymphoepithelial lesions was noted in spite of almost complete depletion of B lymphocytes from the normal gastric mucosa, suggesting either recirculation of MALT lymphoma cells to these lesions or defining lymphoepithelial lesions as a sanctuary site from rituximab penetration. (icr.ac.uk)
  • patients
  • PATIENTS AND METHODS: The study group included 467 patients with PCBCL who were referred, treated, and observed in 11 Italian centers (the Italian Study Group for Cutaneous Lymphomas) during a 24-year period (1980 to 2003). (unipv.it)
  • Results: A total of 9 patients with advanced MALT lymphoma undergoing therapy with single-agent rituximab were identified. (icr.ac.uk)
  • Follow-up biopsies for histological assessment were available in 5 patients with gastric lymphoma. (icr.ac.uk)
  • Conclusion: Rituximab had only moderate activity in terms of inducing objective responses in our unselected and heterogeneous cohort of patients with disseminated MALT lymphoma. (icr.ac.uk)